Table 1 Clinical characteristics of patients with T4 UICC II colon cancer. Patients over 80 years of age and those who died within 30 days after the diagnosis were excluded
From: Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer
Chemotherapy | ||||||||
|---|---|---|---|---|---|---|---|---|
+ CTX | − CTX | Total | Chi square | |||||
N | % | N | % | N | % | p-value | ||
Sex | male | 47 | 59.5 % | 97 | 60.2 % | 144 | 60.0 % | 0.910697 |
female | 32 | 40.5 % | 64 | 39.8 % | 96 | 40.0 % | ||
Age at diagnosis | 30–39 | 2 | 2.5 % | 1 | 0.6 % | 3 | 1.3 % | |
40–49 | 7 | 8.9 % | 9 | 5.6 % | 16 | 6.7 % | ||
50–59 | 16 | 20.3 % | 14 | 8.7 % | 30 | 12.5 % | 0.030225 | |
60–69 | 28 | 35.4 % | 61 | 37.9 % | 89 | 37.1 % | ||
70–79 | 26 | 32.9 % | 76 | 47.2 % | 102 | 42.5 % | ||
Diagnosis ICD-10 | C18.0 caecum | 14 | 17.7 % | 31 | 19.3 % | 45 | 18.8 % | |
C18.1 appendix | 3 | 3.8 % | 5 | 3.1 % | 8 | 3.3 % | ||
C18.2 ascending colon | 14 | 17.7 % | 23 | 14.3 % | 37 | 15.4 % | ||
C18.3 hepatic flexure | 2 | 2.5 % | 14 | 8.7 % | 16 | 6.7 % | ||
C18.4 transverse colon | 5 | 6.3 % | 18 | 11.2 % | 23 | 9.6 % | 0.258347 | |
C18.5 splenic flexure | 3 | 3.8 % | 11 | 6.8 % | 14 | 5.8 % | ||
C18.6 descending colon | 5 | 6.3 % | 11 | 6.8 % | 16 | 6.7 % | ||
C18.7 sigmoid colon | 32 | 40.5 % | 41 | 25.5 % | 73 | 30.4 % | ||
C18.8 overlapping sites of colon | 1 | 1.3 % | 6 | 3.7 % | 7 | 2.9 % | ||
C18.9 colon. unspecified | 0 | 0.0 % | 1 | 0.6 % | 1 | 0.4 % | ||
Grading | 2 | 56 | 70.9 % | 125 | 77.6 % | 181 | 75.4 % | 0.253519 |
3 | 23 | 29.1 % | 36 | 22.4 % | 59 | 24.6 % | ||
Lymphnodes examined | 1–11 | 4 | 5.1 % | 11 | 6.8 % | 15 | 6.3 % | |
12–23 | 44 | 55.7 % | 95 | 59.0 % | 139 | 57.9 % | 0.806346 | |
24+ | 30 | 38.0 % | 52 | 32.3 % | 82 | 34.2 % | ||
unknown | 1 | 1.3 % | 3 | 1.9 % | 4 | 1.7 % | ||
Lymph vessel invasion | L0 | 30 | 38.0 % | 62 | 38.5 % | 92 | 38.3 % | 0.758440 |
L1 | 37 | 46.8 % | 69 | 42.9 % | 106 | 44.2 % | ||
LX | 12 | 15.2 % | 30 | 18.6 % | 42 | 17.5 % | ||
Vein invasion | V0 | 53 | 67.1 % | 92 | 57.1 % | 145 | 60.4 % | 0.068554 |
V1 | 12 | 15.2 % | 18 | 11.2 % | 30 | 12.5 % | ||
VX | 14 | 17.7 % | 51 | 31.7 % | 65 | 27.1 % | ||
Recurrence | no | 63 | 79.7 % | 138 | 85.7 % | 201 | 83.8 % | 0.238964 |
yes | 16 | 20.3 % | 23 | 14.3 % | 39 | 16.3 % | ||
Locoregional recurrence | no | 72 | 91.1 % | 154 | 95.7 % | 226 | 94.2 % | 0.160988 |
yes | 7 | 8.9 % | 7 | 4.3 % | 14 | 5.8 % | ||
Distant recurrence | no | 67 | 84.8 % | 146 | 90.7 % | 213 | 88.8 % | 0.176026 |
yes | 12 | 15.2 % | 15 | 9.3 % | 27 | 11.3 % | ||
Vital status | alive | 65 | 82.3 % | 105 | 65.2 % | 170 | 70.8 % | 0.006285 |
dead | 14 | 17.7 % | 56 | 34.8 % | 70 | 29.2 % | ||
Death or recurrence | no | 58 | 73.4 % | 95 | 59.0 % | 153 | 63.8 % | 0.029079 |
yes | 21 | 26.6 % | 66 | 41.0 % | 87 | 36.3 % | ||
Total | 79 | 100.0 % | 161 | 100.0 % | 240 | 100.0 % | ||